
|Articles|December 15, 2002
Novartis Transfers Apligraf
Boston - Although officials are mum on details, product quality appears to be one factor in the transfer of worldwide marketing of Apligraf from Novartis Inc. back to Organogenesis, which develops the engineered skin and is solely responsible for its manufacture.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
Dermatology Conferences and Meetings Calendar: December 2025
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5


















